Atlas Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Atlas Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-650	Closed	-$18.7K	–	896
2024 Q1	$18.7K	Hold	650	–	–	﹤0.01%	671
2023 Q4	$21.3K	Hold	650	–	–	﹤0.01%	683
2023 Q3	$18.1K	Hold	650	–	–	﹤0.01%	647
2023 Q2	$22.2K	Hold	650	–	–	﹤0.01%	670
2023 Q1	$19.5K	Hold	650	–	–	﹤0.01%	685
2022 Q4	$18.3K	Hold	650	–	–	﹤0.01%	668
2022 Q3	$21.4K	Hold	650	–	–	﹤0.01%	648
2022 Q2	$20.5K	Buy	+650	New	+$22.7K	﹤0.01%	680

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $3.3B AUM 33.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Atlas Capital Advisors's ARKG Position: Q2 2024 in Review

Atlas Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 650 shares — an estimated $18.7K sold.

Atlas Capital Advisors first reported a position in ARKG in Q2 2022 and held it in 8 quarters. The position peaked at $22.2K in Q2 2023. 263 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

Atlas Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
Atlas Capital Advisors sold 650 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $18.7K.
Atlas Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2022 and held it in 8 quarters.
Atlas Capital Advisors's ARK Genomic Revolution ETF position peaked at $22.2K in Q2 2023.
263 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Atlas Capital Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.